Literature DB >> 34460429

Randomized Controlled Trials on COVID-19 Should Be Accurate and Trustworthy.

Ben W Mol.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 34460429      PMCID: PMC8733489          DOI: 10.4269/ajtmh.21-0836a

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


× No keyword cloud information.
Dear Sir, Abd-Elsalam et al. recently published a randomized clinical trial on the effectiveness of hydroxychloroquine in patients with COVID-19. I read their article with interest and came across some inconsistencies in the data provided. In particular, I have the following concerns: The timelines in the study seem not feasible. The study states that participants in the study were “admitted between March and June 2020,” and then states, “All the patients were followed up for 4 weeks.” The article was received by the Journal on July 17, 2020. This raises the question of how follow-up could have been completed by mid-July, with all data analyzed. The study recruited similar patients in the same period in the same centers for two other studies., Could the authors explain how it was decided to which study a patient was recruited? According the trial registry (NCT04353336), the study was set to continue until September 23, 2030. The trial registry also specifies the initial sample size as 40 (NCT04353336), which appears to have been changed to 200 after completion of the recruitment. The article does not provide a prospective sample size calculation. Would the authors be able to provide an explanation on how they calculated the 15 P values in Table 2? My own calculations led to considerably different results. Some of the study data appear improbable. There are nine instances of a P value between 0.05 and 0.10, four with a P value of 0.07 in Table 2. Multiple variables have similar decimals (i.e., 0.26 and 28.17), and there are widely different SDs between groups (i.e., 13.45 versus 179.2). Might some values have been duplicated in error? Would the authors be able to explain the 20% difference in recovery rate between study arms, without any difference in “duration to clinical improvement” or “duration to hospital discharge” (Table 3)? I encourage the authors to share their original data and to provide clarification, based on the concerns listed here, to support the remarkable results of this study.
  3 in total

1.  Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.

Authors:  Hany M Dabbous; Sherief Abd-Elsalam; Manal H El-Sayed; Ahmed F Sherief; Fatma F S Ebeid; Mohamed Samir Abd El Ghafar; Shaimaa Soliman; Mohamed Elbahnasawy; Rehab Badawi; Mohamed Awad Tageldin
Journal:  Arch Virol       Date:  2021-01-25       Impact factor: 2.574

2.  Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.

Authors:  Sherief Abd-Elsalam; Eslam Saber Esmail; Mai Khalaf; Ehab Fawzy Abdo; Mohammed A Medhat; Mohamed Samir Abd El Ghafar; Ossama Ashraf Ahmed; Shaimaa Soliman; Ghada N Serangawy; Mohamed Alboraie
Journal:  Am J Trop Med Hyg       Date:  2020-10       Impact factor: 3.707

3.  Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.

Authors:  Hany M Dabbous; Manal H El-Sayed; Gihan El Assal; Hesham Elghazaly; Fatma F S Ebeid; Ahmed F Sherief; Maha Elgaafary; Ehab Fawzy; Sahar M Hassany; Ahmed R Riad; Mohamed A TagelDin
Journal:  Sci Rep       Date:  2021-03-31       Impact factor: 4.379

  3 in total
  1 in total

1.  Response to "Randomized Controlled Trials on COVID-19 Should be Accurate and Trustworthy".

Authors:  Sherief Abd-Elsalam; Shaimaa Soliman
Journal:  Am J Trop Med Hyg       Date:  2021-08-30       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.